InterAx Biotech and Boehringer Ingelheim are collaborating. According to a press release, the German pharma company will use the proprietary InterAx systems biology platform to characterize a drug candidate for an undisclosed target.
InterAx Biotech is a spin-off from the Swiss Federal Institute of Technology Zurich (ETH) and the Paul Scherrer Institute (PSI). The platform of the Villigen-based company is intended to speed up the discovery of novel drug candidates, with the focus on G protein-coupled receptors (GPCRs). These transmit the signals of active substances from the outside to the inside of the cell and trigger reactions in it.
InterAx Biotech has already won over several investors with its platform. At the beginning of the year the company secured 3 million Swiss francs in a financing round. The round was led by the US venture capital company Falcon III Ventures and investiere.ch.